[
    [
        {
            "time": "2021-11-30",
            "original_text": "恒瑞医药(SH600276)药品在SHR8058-301主要研究终点结果达到方案预设的优效标准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR8058",
                    "临床试验",
                    "优效标准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(SH600276)药品在SHR8058-301主要研究终点结果达到方案预设的优效标准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "恒瑞医药(SH600276)研发的SHR8058滴眼液治疗睑板腺功能障碍相关干眼病Ⅲ期临床试验(SHR8058-301)主要研究终点结果达到方案预设优效标准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR8058",
                    "滴眼液",
                    "临床试验",
                    "优效标准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(SH600276)研发的SHR8058滴眼液治疗睑板腺功能障碍相关干眼病Ⅲ期临床试验(SHR8058-301)主要研究终点结果达到方案预设优效标准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "恒瑞医药(SH600276)：‘SHR-1909注射液’获药物临床试验批准通知书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR-1909",
                    "注射液",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(SH600276)：‘SHR-1909注射液’获药物临床试验批准通知书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "恒瑞医药开展PD-L1单抗联合抗肿瘤活菌药物的全球临床研究有望为复发难治肿瘤患者带来新希望",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PD-L1",
                    "单抗",
                    "抗肿瘤",
                    "临床研究"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药开展PD-L1单抗联合抗肿瘤活菌药物的全球临床研究有望为复发难治肿瘤患者带来新希望",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "恒瑞医药收监管函！问询",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "监管函",
                    "问询"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药收监管函！问询",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "上交所向恒瑞医药下发监管函，微信群聊将试行打开电商类外链，抖音短剧或将开启付费模式",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "监管函",
                    "上交所",
                    "微信群聊",
                    "抖音短剧"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "上交所向恒瑞医药下发监管函，微信群聊将试行打开电商类外链，抖音短剧或将开启付费模式",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "3200亿医药巨头被监管，影响多大？",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "监管",
                    "医药巨头"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3200亿医药巨头被监管，影响多大？",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]